Concepedia

Paolo Caimi

PC

Statistics

Publications

6

Citations

386

H-Index

6

Active since

2014

Affiliations

Case Western Reserve University(Current)

University Hospitals Seidman Cancer Center

University Hospitals of Cleveland

Cleveland Clinic

Texas Oncology

Paolo Caimi is an author at Case Western Reserve University specializing in medicine, oncology, and refractory hodgkin lymphoma.

Publications per year

2014–2022

6

Publications

6

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas et al. · Blood · 2018 · 253 citations · Full text

, , +14

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, Graham P. Collins, Felipe Samaniego et al. · Blood · 2018 · 41 citations

, , +17

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Allison Winter, Daniel J. Landsburg, Anthony R. Mato et al. · Blood · 2017 · 34 citations · Full text

, , +9

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann S. LaCasce, R. Gregory Bociek, Jeffrey Matous et al. · Blood · 2014 · 24 citations

, , +15

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes

Jonathan E. Brammer, Dai Chihara, Limei Poon et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 20 citations · Full text

, , +11

1–5 of 6